(2-amino-4-(arylamino)phenyl carbamates

1. A compound, or pharmaceutically acceptable salt thereof, having a formula I of:

wherein R 1 is H or optionally-substituted alkyl;

R 2 is optionally-substituted alkyl;

R 3 and R 4 are each independently H or optionally-substituted alkyl;

R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl;

R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle;

R 8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R 8 is 4-halophenyl, then R 2 is substituted alkyl having one or more hydrogen atoms substituted with a substituent selected from halogen, cycloalkyl, alkoxy, amino, hydroxyl, aryl, alkenyl, or carboxyl, or at least one of R 6 or R 7 is not H;

R 30 and R 31 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy; and

R 32 is deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.

2. A compound, or a pharmaceutically acceptable salt thereof, having a formula II of:

wherein R 1 is H or optionally-substituted alkyl;

R 2 is optionally-substituted alkyl;

R 3 and R 4 are each independently H or optionally-substituted alkyl;

R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl;

R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle; and

R 8 is optionally-substituted thiazolyl.

3. The compound of claim 1 , wherein R 1 is H.

4. The compound of claim 1 , wherein R 2 is C 1 -C 6 alkyl.

5. The compound of claim 4 , wherein R 2 is carbocyclic-substituted alkyl or heterocyclic-substituted alkyl.

6. The compound of claim 1 , wherein R 3 and R 4 are each H.

7. The compound of claim 1 , wherein R 5 is H.

8. The compound of claim 1 , wherein R 6 and R 7 are both H; R 6 and R 7 are both deuterium; R 6 and R 7 together form a cycloalkyl; or at least one of R 6 or R 7 is a substituted alkyl.

9. The compound of claim 1 , wherein R 8 is selected from:

wherein R 9 -R 25 are each independently H, halogen, optionally-substituted sulfanyl, or optionally-substituted alkyl.

10. The compound of claim 9 , wherein R 8 is:

wherein at least one of R 9 or R 10 is halogen.

11. The compound of claim 9 , wherein R 8 is:

wherein at least one of R 19 or R 20 is halogen.

12. The compound of claim 9 , wherein R 8 is:

wherein at least one of R 14 -R 18 is substituted sulfanyl or haloalkyl; or wherein R 16 is F.

13. The compound of claim 12 , wherein at least one of R 14 -R 18 is —SF 5 or CF 3 .

14. The compound of claim 9 , wherein R 8 is:

wherein at least one of R 11 -R 13 or R 23 -R 25 is substituted sulfanyl.

15. The compound of claim 1 , wherein R 8 is:

wherein at least one of R 14 -R 18 is halo-substituted sulfanyl, haloalkyl or halogen.

16. The compound of claim 15 , wherein at least one of R 14 -R 18 is —SF 5 or —CF 3 .

17. The compound of claim 16 , wherein R 15 , R 16 , or R 17 is —SF 5 or —CF 3 .

18. The compound of claim 1 , wherein R 32 is —F, and R 30 and R 31 are each H.

19. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:

20. A pharmaceutical composition comprising at least one compound of claim 1 , and at least one pharmaceutically acceptable additive.

21. A method of treating tinnitus in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of at least one compound of claim 1 .

22. A method comprising treating a subject suffering from or susceptible to conditions that are ameliorated by Kv7.2/3 potassium channel opening, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 .

23. A method of producing an anti-epileptic, muscle relaxing, fever reducing, peripherally analgesic or anti-convulsive effect in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of compound of claim 1 .

24. A method for treating epilepsy in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1 .

25. A compound, or pharmaceutically acceptable salt thereof, having a formula of:

wherein R 1 is H or optionally-substituted alkyl;

R 2 is substituted alkyl having one or more hydrogen atoms substituted with a substituent selected from halogen, cycloalkyl, alkoxy, amino, hydroxyl, aryl, alkenyl, or carboxyl;

R 3 and R 4 are each independently H or optionally-substituted alkyl;

R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl;

R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle;

R 8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl; and

R 30 , R 31 and R 32 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.

26. A compound, or pharmaceutically acceptable salt thereof, having a formula of:

wherein R 1 is H or optionally-substituted alkyl;

R 2 is optionally-substituted alkyl;

R 3 and R 4 are each independently H or optionally-substituted alkyl;

R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl;

R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle, provided at least one R 6 or R 7 is not H;

R 8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R 8 is 4-halophenyl, then R 2 is substituted alkyl or branched alkyl or at least one of R 6 or R 7 is not H; and

R 30 , R 31 and R 32 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.

27. A compound, or a pharmaceutically acceptable salt thereof, having a formula of:

wherein R 1 is H or optionally-substituted alkyl;

R 2 is optionally-substituted alkyl;

R 3 and R 4 are each independently H or optionally-substituted alkyl;

R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl;

R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle; and

R 8 is substituted thiophenyl, wherein at least one substituent on the thiophenyl is halo-substituted sulfanyl.

28. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:

29. A compound, or pharmaceutically acceptable salt thereof, having a formula I of:

wherein R 1 is H or optionally-substituted alkyl;

R 2 is optionally-substituted alkyl;

R 3 and R 4 are each independently H or optionally-substituted alkyl;

R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl;

R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle;

R 8 is

 wherein at least one of R 14 -R 18 is substituted sulfanyl or haloalkyl; and

R 3 and R 31 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy; and

R 32 is deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.

30. The compound of claim 29 , wherein R 32 is halogen.

31. The compound of claim 29 , wherein R 32 is —F.

32. The compound of claim 29 , wherein at least one of R 14 -R 18 is halo-substituted sulfanyl.

33. The compound of claim 29 , wherein at least one of R 14 -R 18 is haloalkyl.

34. The compound of claim 29 , wherein at least one of R 14 -R 18 is —SF 5 .

35. The compound of claim 29 , wherein at least one of R 14 -R 18 is —CF 3 .

36. The compound of claim 29 , wherein R 16 is —SF 5 .

37. The compound of claim 29 , wherein R 16 is —CF 3 .

38. The compound of claim 29 , wherein R 2 is alkyl.

39. The compound of claim 29 , wherein R 2 is C 1 -C 6 alkyl.

40. The compound of claim 29 , wherein R 2 is ethyl.

41. The compound of claim 29 , wherein R 3 , R 4 , R 5 , R 6 , and R 7 are each H.

42. The compound of claim 41 , wherein R 32 is —F and R 16 is —CF 3 .

43. The compound of claim 42 , wherein R 2 is alkyl.

44. The compound of claim 43 , wherein R 3 and R 31 are each H.

45. The compound of claim 29 , wherein R 15 , R 16 , or R 17 is —SF 5 or —CF 3 .

46. The compound of claim 45 , wherein R 1 , R 1 , R 3 , R 4 , R 5 , R 6 , and R 7 are each H; R 2 is alkyl; and R 32 is —F.

47. A method for treating bipolar disorder in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1 .

48. A method of producing an anti-epileptic effect in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of compound of claim 1 .

49. A method of treating tinnitus in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of at least one compound of claim 12 .

50. A method of treating epilepsy in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of at least one compound of claim 12 .